

CONTENTS

Dedications	v
Preface	vii
About the Author	xiii
1 <i>Beta-Blockers: The Cornerstone of Cardiac Drug Therapy</i>	1
<i>New Concepts</i>	1
<i>Beta-Receptors</i>	4
<i>Mechanism of Action</i>	6
<i>Dosage Considerations</i>	7
<i>Pharmacologic Properties and Clinical Implications</i>	8
<i>Salutary Effects of Beta-Adrenergic Blockade</i>	13
<i>Beta-Blockers versus Calcium Antagonists and Oral Nitrates</i>	15
<i>Indications for Beta-Blockers</i>	16
<i>Advice and Adverse Effects</i>	20
<i>Individual Beta-Blockers</i>	23
<i>Which Beta-Blocker Is Best for Your Patients?</i>	31
2 <i>Beta-Blocker Controversies</i>	37
<i>Beta-Blockers Are Not a Good Initial Choice for Hypertension:</i> <i>True or False?</i>	37
<i>Beta-Blockers Are Not Recommended for Treatment</i> <i>of Elderly Hypertensives: True or False?</i>	38
<i>Beta-Blockers Cause Diabetes: True or False?</i>	39
<i>Do All Beta-Blockers Cause Glucose Intolerance?</i>	40
<i>Beta-Blockers Should Not Be Given to Patients During</i> <i>the Early Hours of Acute MI: True or False?</i>	41
3 <i>Angiotensin-Converting Enzyme Inhibitors and</i> <i>Angiotensin II Receptor Blockers</i>	43
<i>Mechanism of Action</i>	43
<i>ACE Inhibitors versus Other Vasodilators</i>	46
<i>Clinical Indications</i>	47
<i>Contraindications</i>	50
<i>Advice, Adverse Effects, and Interactions</i>	51
<i>Individual ACE Inhibitors</i>	53
<i>Angiotensin II Receptor Blockers</i>	58
4 <i>ACE Inhibitor Controversies</i>	63
<i>ACE Inhibitors versus ARBs: Does the Choice Matter?</i>	63
<i>ACE Inhibitors/ARBs Cause Renoprotection: True or False?</i>	63
<i>ACE Inhibitors Decrease the Incidence of Diabetes: True or False?</i>	64
<i>Combination of ACE Inhibitor and ARB Proven Effective:</i> <i>True or False?</i>	64
<i>ACE Inhibitors for HF with Preserved Systolic Function</i>	65
5 <i>Calcium Antagonists (Calcium Channel Blockers)</i>	67
<i>Mechanism of Action</i>	67

	<i>Major Calcium Antagonists</i>	68
	<i>When to Choose a Calcium Antagonist</i>	75
	<i>Indications for Calcium Antagonists</i>	75
	<i>Which Calcium Antagonist to Choose</i>	77
	<i>Combination of Calcium Antagonists with Beta-Blockers, Nitrates, or Digoxin</i>	77
6	<i>Calcium Antagonists Controversies</i>	81
	<i>Calcium Antagonists and Heart Failure</i>	81
	<i>Are Calcium Antagonists Useful for Hypertensives with CAD?</i>	82
7	<i>Diuretics</i>	85
	<i>Indications</i>	85
	<i>Thiazides</i>	87
	<i>Loop Diuretics</i>	87
	<i>Potassium-Sparing Diuretics</i>	91
	<i>Other Diuretics</i>	94
	<i>Potassium Chloride Supplements</i>	95
	<i>New Concepts</i>	98
8	<i>Hypertension</i>	103
	<i>Relevant Key Issues</i>	103
	<i>Definitions</i>	105
	<i>Nondrug Therapy</i>	106
	<i>Laboratory Work-Up</i>	107
	<i>Which Drugs to Choose</i>	107
	<i>Beta-Blockers</i>	115
	<i>Diuretics</i>	117
	<i>ACE Inhibitors and Angiotensin II Receptor Blockers</i>	121
	<i>Calcium Antagonists (Extended Release)</i>	124
	<i>Centrally Acting Drugs</i>	125
	<i>Alpha₁-Blockers</i>	126
	<i>Hypertensive Crisis</i>	127
9	<i>Hypertension Controversies</i>	137
	<i>Beta-Blockers Should Not Remain First Choice in the Treatment of Primary Hypertension: True or False?</i>	137
	<i>Diabetic Risk with Beta-Blockers and Diuretics</i>	141
	<i>Hypertensive Agents Increase Heart Failure Risk: True or False?</i>	146
	<i>Is Angioedema a Significant Risk with ACE Inhibitors?</i>	147
	<i>Age and Ethnicity Hold the Key for Drug Choice</i>	147
	<i>Recommendations for Future Randomized Trials</i>	153
10	<i>Management of Angina</i>	159
	<i>Salient Clinical Features</i>	159
	<i>Treatment of Stable Angina</i>	160
	<i>Management of Unstable Angina</i>	169
	<i>Variant Angina (Prinzmetal's)</i>	175
	<i>Controversies</i>	177
11	<i>Management of Acute Myocardial Infarction</i>	183
	<i>Diagnosis</i>	183
	<i>Genomics</i>	183
	<i>Relevant Key Strategies</i>	184
	<i>Limitation of Infarct Size and Increased Survival</i>	188
	<i>Percutaneous Coronary Intervention</i>	189
	<i>Thrombolytic Therapy</i>	189
	<i>Antithrombins</i>	193

	<i>Beta-Blockers</i>	194
	<i>Ace Inhibitors</i>	195
	<i>Nitrates</i>	195
	<i>Statins</i>	196
	<i>Magnesium</i>	196
	<i>Management of Complications of Infarction</i>	197
	<i>Management of Non-ST-Elevation Myocardial Infarction</i>	204
	<i>Changing Strategies</i>	206
12	Management of Heart Failure	211
	<i>The Size of the Problem</i>	211
	<i>Causes of Heart Failure</i>	211
	<i>Diagnosis</i>	214
	<i>Pathophysiology</i>	216
	<i>Management Guide</i>	217
	<i>Vasodilators</i>	218
	<i>Diuretics</i>	221
	<i>Aldosterone Antagonists</i>	222
	<i>Beta-Blockers</i>	223
	<i>Inotropic Agents</i>	225
	<i>ACC/AHA Guidelines</i>	233
	<i>Management of Pulmonary Edema</i>	236
13	Heart Failure Controversies	241
	<i>Management of Heart Failure Preserved Ejection</i>	
	<i>Fractions (HFPEF)</i>	241
	<i>Digoxin Is Not Useful for HFPEF: True or False?</i>	243
	<i>Is CHARM-Preserved a Clear Study of HFPEF?</i>	244
	<i>Does an ACE Inhibitor Combined with an ARB</i>	
	<i>Improve Outcomes?</i>	244
	<i>Aldosterone Antagonists: Useful but Harmful?</i>	245
	<i>Heart Failure in Blacks: Do Differences Exist?</i>	245
	<i>Should the Role of Natriuretic Peptides Be Expanded?</i>	246
	<i>Is Nesiritide a Useful Addition?</i>	246
	<i>Are Statins Recommended for Patients with Heart Failure?</i>	247
14	Management of Cardiac Arrhythmias	249
	<i>Classification</i>	250
	<i>Diagnosis of Arrhythmias</i>	251
	<i>Management of Supraventricular Arrhythmias</i>	253
	<i>Ventricular Arrhythmias</i>	264
	<i>Ventricular Tachycardia</i>	264
15	Cardiac Arrest	285
	<i>Life-Saving Procedures</i>	286
	<i>Drug Therapy</i>	290
16	Management of Infective Endocarditis	297
	<i>Classification and Diagnosis</i>	297
	<i>Therapy</i>	299
	<i>Prophylaxis of Bacterial Endocarditis</i>	305
17	Management of Dyslipidemias	307
	<i>Diagnosis</i>	308
	<i>Dietary Therapy</i>	309
	<i>Guidelines for Drug Therapy</i>	311
	<i>Statins</i>	311
	<i>Combination Therapy</i>	315

	<i>Nicotinic Acid</i>	317
	<i>Fibrates</i>	317
	<i>Conclusions</i>	318
18	Statin Controversies	323
	<i>High-Intensity Statin Therapy Causes Significant Regression of Coronary Atheroma: True or False?</i>	323
	<i>LDL Cholesterol: How Low Should it Be for Stable CAD Patients?</i>	324
	<i>Rhabdomyolysis Is a Cause for Alarm: True or False?</i>	324
	<i>What About Statin Interactions?</i>	326
	<i>Do Fibrates Have a Small Role in the Treatment of CVD?</i>	327
19	Antiplatelet Agents, Anticoagulants, Specific Thrombin Inhibitors	331
	<i>Antiplatelet Agents</i>	331
	<i>Anticoagulants</i>	341
	<i>Specific Thrombin Inhibitors</i>	344
20	Cardiac Drugs During Pregnancy and Lactation	349
	<i>Antihypertensive Agents in Pregnancy</i>	349
	<i>Drug Therapy for Heart Failure in Pregnancy</i>	355
	<i>Antiarrhythmic Agents in Pregnancy</i>	356
	<i>Cardiac Drugs During Lactation</i>	357
21	Effects of Drug Interactions	363
	<i>Interactions of Cardiovascular Drugs</i>	363
	<i>Antiarrhythmic Agents</i>	365
	<i>Antiplatelet Agents/Anticoagulants</i>	368
	<i>Beta-Blockers</i>	368
	<i>Calcium Antagonists</i>	369
	<i>Digoxin</i>	370
	<i>Diuretics</i>	371
	<i>Nitrates</i>	371
	<i>Lipid-Lowering Agents</i>	371
	<i>Thrombolytic Agents</i>	371
	<i>Interactions of Cardiac and Noncardiac Drugs</i>	371
	<i>Cardiac Effects of Noncardiac Drugs</i>	374
22	Hallmark Clinical Trials	381
	<i>Acute Coronary Syndrome RCTs</i>	381
	<i>Heart Failure RCTs</i>	385
	<i>Aldosterone Antagonist Trials</i>	386
	<i>Hypertension Trials</i>	386
	<i>Statin RCTs</i>	387
	<i>Arrhythmia RCTs</i>	389
	<i>Beta-Blockers and Diabetes</i>	390
	<i>Clopidogrel</i>	390
	<i>Clopidogrel/Beta-Blockers</i>	390
	<i>Folic Acid/B₆/B₁₂</i>	391
	Appendix I: Infusion Pump Charts	395
	Appendix II: Drug Index	397
	Index	405